Sort
51,593 grants matching “hepatitis”
IMMUNE REGULATION AND VACCINE DEVELOPMENT IN LEISHMANIASIS
$724,563David Sacks · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
HIV Disease Outcomes in Drug Users in Clinical Practice
$724,408Richard Douglas Moore · Johns Hopkins University · R01 · FY2010 · DA
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
$724,384Michael Karin · University Of California, San Diego · U01 · FY2020 · AA
Longitudinal evaluation of HIV-associated lung disease phenotypes
$724,214Alison Morris · University Of Pittsburgh At Pittsburgh · R01 · FY2017 · HL
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
$724,197Michael Karin · University Of California, San Diego · U01 · FY2019 · AA
Facilitating islet implantation and engraftment following transplantation using primed umbilical cord mesenchymal stem therapies and focused ultrasound
$724,180Avnesh Sinh Thakor · Stanford University · R01 · FY2025 · DK
Enhancing immune regulation in gene therapy for hemophilia
$724,174Roland W. Herzog · Indiana University Indianapolis · R01 · FY2023 · HL
Gene Therapy in Hutchinson-Gilford Progeria Syndrome
$724,153Jonathan David Brown · Vanderbilt University Medical Center · R01 · FY2023 · HL
Gene Therapy in Hutchinson-Gilford Progeria Syndrome
$724,153Jonathan David Brown · Vanderbilt University Medical Center · R01 · FY2025 · HL
The effects of orange juice compared with sugar-sweetened beverage on risk factors and metabolic processes associated with the development of cardiovascular disease and type 2 diabetes
$724,139Kimber Lee Stanhope · University Of California At Davis · R01 · FY2022 · HL
Obesity complicating type 1 diabetes in young people: Physiology and Impact of GLP-1 analogue anti-obesity treatment on cardiometabolic risk factors
$723,984Michelle Van Name · Yale University · R01 · FY2023 · DK
Technical Validation of MR Biomarkers of Obesity-Associated NAFLD
$723,934Scott B. Reeder · University Of Wisconsin-Madison · R01 · FY2021 · DK
Blood Donor Competence, Autonomy and Relatedness Enhancement (Blood Donor CARE)
$723,927Christopher R France · Ohio University Athens · R01 · FY2018 · HL
Monkey Alcohol Tissue Research Resource (MATRR)
$723,781Kathleen A Grant · Oregon Health & Science University · R24 · FY2014 · AA
Developmental Funds
$723,708Diane M Simeone · University Of California, San Diego · P30 · FY2024 · CA
Gut flora metabolism of dietary phosphatidylcholine and cardiovascular disease
$723,542Stanley L Hazen · Cleveland Clinic Lerner Com-Cwru · R01 · FY2012 · HL
Accelerating Wound Healing through RNAi
$723,483Brian H. Johnston · Somagenics, Inc. · R44 · FY2014 · GM
Nuclear Receptor Functional Profiling in Metabolism and Disease
$723,430Ronald M. Evans · Baylor College Of Medicine · U19 · FY2007 · DK
The Progression of Hepatitis C Among IDUs
$723,353David L Thomas · Johns Hopkins University · R01 · FY2011 · DA
Hepatitis C Pathogenesis and the Human Genome
$723,283David L Thomas · Johns Hopkins University · R01 · FY2010 · DA
Clinical & Immunological Study of Treatment Withdrawal in E-Ag Negative Hepatitis B
$723,268Stewart Cooper · California Pacific Med Ctr Res Institute · R01 · FY2025 · DK
Clinical & Immunological Study of Treatment Withdrawal in E-Ag Negative Hepatitis B
$723,189Stewart Cooper · California Pacific Med Ctr Res Institute · R01 · FY2017 · DK
Maintenance of Animal Models of Human Hemophilia and VWD
$722,913Timothy Charles Nichols · Univ Of North Carolina Chapel Hill · R24 · FY2012 · HL
Novel Pathogen Associated Cancers (PQ12)
$722,856Denise A. Galloway · Fred Hutchinson Cancer Research Center · R01 · FY2014 · CA
Deep Phenotyping of ANGPTL3, ANGPTL4 and ANGPTL8 Human Knockouts and Population Based Studies
$722,788Daniel James Rader · University Of Pennsylvania · R01 · FY2020 · HL